Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Hepatitis C, Chronic
Interventions
DRUG

GS-5885 tablet

30 mg active tablet

DRUG

GS-9451 tablet

two active 100 mg tablets

BIOLOGICAL

peginterferon alfa-2a

peginterferon alfa-2a (solution for injection) 180 µg/week

DRUG

ribavirin tablet

ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet

Trial Locations (55)

10016

Concorde Medical Group, New York

10021

Cornell University Gastroenterology & Hepatology, New York

11030

North Shore University Hospital, Manhasset

13903

Binghamton Gastroenterology, Binghamton

21229

Digestive Disease Associates, PA, Baltimore

22031

Metropolitan Research, Fairfax

23249

Liver Institute of Virginia, Richmond

23502

Digestive and Liver Disease Specialists, Norfolk

27710

Duke University Medical Center, Durham

28304

Cumberland Research Associates, LLC, Fayetteville

28801

Asheville Gastroenterology Associates, P.A., Asheville

30033

Dekalb Gastroenterology, Decatur

30060

Gastrointestinal Specialists of Georgia PC, Marietta

30308

Emory University, Infectious Disease Clinic, Atlanta

30309

Digestive Healthcare of Georgia, Atlanta

32610

University of Florida, Gainesville

32803

Orlando Immunology Center, Orlando

33136

University of Miami, Miami

33414

South Florida Center of Gastroenterology, LLC, Wellington

34209

Bach and Godofsky Infectious Diseases, Bradenton

36116

Alabama Liver and Digestive Specialists, Montgomery

36305

Digestive Health Specialists of the Southeast, Dothan

37203

Columbia Medical Group, The Frist Clinic, Nashville

37205

Nashville Medical Research Institute, Nashville

37211

Nashville Gastrointestinal Specialists, Inc, Nashville

38138

Memphis Gastroenterology Group, Germantown

38801

Digestive Health Specialists, PA, Tupelo

39202

Gastrointestinal Associates, PA, Jackson

42101

Graves Gilbert Clinic, Bowling Green

45267

University of Cincinnati, Cincinnati

46202

Indiana University, Indianapolis

46237

Indianapolis Gastroenterology Research Foundation, Indianapolis

48202

Henry Ford Health System, Detroit

70809

Gastroenterology Associates, LLC, Baton Rouge

74104

Options Health Research, LLC, Tulsa

75246

Baylor University Medical Center, Dallas

76012

The North Texas Research Institute, Arlington

77005

Kelsey Research Foundation, Houston

77030

Research Specialists of Texas, Houston

80045

University of Colorado Denver, Aurora

80110

South Denver Gastroenterology, Englewood

87505

Southwest CARE Center, Santa Fe

90211

California Liver Institute, Beverly Hills

92015

RESEARCH and EDUCATION, INC, San Diego

92037

Scripps Clinic, La Jolla

92123

Medical Associates Research Group, San Diego

92154

Kaiser Permanente, San Diego

95817

University of California Davis Medical Center, Sacramento

98101

Virginia Mason Medical Center, Digestive Disease Institute, Seattle

02115

Beth Israel Deaconess Medical Center, Boston

01608

Partners in Internal Medicine, P.C., Worcester

08844

ID Care 105, Hillsborough

07960

Atlantic Research Affiliates, LLC, Morristown

02905

University Gastroenterology, Providence

00927

Fundacion de Investigacion de Diego, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY